ArticleBiosensors2025
Visible-Light Hyperspectral Reconstruction and PCA-Based Feature Extraction for Malignant Pleural Effusion Cytology.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluation of the Usefulness of Machine Learning and Artificial Intelligence on Hyperspectral Images in the Diagnosis of Myelodysplastic Syndrome.Journal of biophotonics · 2026Article
- Hyperspectral imaging system for multiplexed cancer marker detection: design and clinical evaluation.Journal of biomedical optics · 2026Article
- Diagnostic Yield of Malignant Pleural Effusion in Various Primary and Metastatic Cancers: Insights Across Cancer Subtypes.Pulmonary medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Malignant pleural effusion, commonly referred to as MPE, is a prevalent complication associated with individuals diagnosed with neoplastic disorders. The data acquired by pleural fluid cytology is beneficial for diagnostic objectives. Consequently, the initial step in the diagnostic procedure for lung cancer is the analysis of pleural effusion fluid. This research aims to provide a cutting-edge model for analyzing PE cytology images. This model utilizes a computer-aided diagnosis (CAD) system that integrates hyperspectral imaging (HSI) technology for the classification of spectral variations. Giemsa, which is one of the most popular microscopic stains, is employed to stain the samples, after which a sensitive CCD mounted on a microscope captures the images. Subsequently, the HSI model is tasked with obtaining the image spectra. Principal Component Analysis (PCA) constitutes the concluding phase in the classification procedure of various cell types. We expect that the suggested technique will enable medical professionals to stage lung cancer more rapidly. In the future, we aspire to develop an extensive data system that utilizes deep learning techniques to facilitate the automatic classification of cells, thereby ensuring the most precise diagnosis. Furthermore, enhancing accuracy and minimizing data dimensions are important priorities to accelerate diagnostics, conserve resources, and reduce computing time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.